KEYNOTE-564 follow-up shows OS and DFS gains with adjuvant pembrolizumab in high-risk ccRCC, plus guidance on relapse after therapy. In the adjuvant setting, managing the patient with high-risk clear ...
At Quinnipiac, we provide the knowledge and resources you need to make a tangible impact on your chosen field. Through a combination of classroom theory and practical experience designed for you to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results